Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 28;26(2):349.
doi: 10.3892/ol.2023.13935. eCollection 2023 Aug.

Natural products as drug candidates for breast cancer (Review)

Nitin T Telang  1
Affiliations
Review

Natural products as drug candidates for breast cancer (Review)

Nitin T Telang. Oncol Lett. .

Abstract

Progression of early-stage breast cancer to advanced-stage metastatic disease represents a major cause of death in women. Long-term conventional and targeted therapy for breast cancer includes multi-drug combinations of cytotoxic chemotherapeutics and pathway-selective small molecule inhibitors. These treatment options are frequently associated with systemic toxicity, intrinsic/acquired therapy resistance and emergence of a drug-resistant cancer stem cell population. This stem cell population has a chemo-resistant, cancer-initiating, premalignant phenotype that is accompanied by cellular plasticity and metastatic potential. These limitations emphasize an unmet need to identify testable alternatives against therapy-resistant metastatic breast cancer. Natural products such as dietary phytochemicals, nutritional herbs and their constitutive bioactive agents have documented human consumption, and lack detectable systemic toxicity and resultant off-target unfavorable side effects. Because of these advantages, natural products may represent testable alternatives for therapy-resistant breast cancer. The present review discusses published evidence for growth inhibitory efficacy of natural products on cellular models for molecular subtypes of clinical breast cancer and development of drug-resistant stem cell models. Collectively, this evidence validates mechanism-based experimental approaches to screen and prioritize efficacious bioactive agents from natural products as novel drug candidates that may function as therapeutic alternatives for breast cancer.

Keywords: breast cancer; drug candidates; herbal extracts; natural products.

PubMed Disclaimer

Conflict of interest statement

The author declares that they have no competing interests.

References

    1. American Cancer Society, corp-author. American Cancer Society, Inc.; Atlanta, GA: 2022. American Cancer Society Facts and Figures-2022.
    1. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–10874. doi: 10.1073/pnas.191367098. - DOI - PMC - PubMed
    1. Dean M, Fojo T, Bates S. Tumor stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–284. doi: 10.1038/nrc1590. - DOI - PubMed
    1. Patel SA, Ndabbahaliye A, Lim PK, Milton R, Rameshwar P. Challenges in the development of future treatments for breast cancer stem cells. Breast Cancer (Dove Med Press) 2010;2:1–11. - PMC - PubMed
    1. Hong M, Tan HY, Li S, Cheung F, Wang N, Nagamatsu T, Feng Y. Cancer stem cells: Potential targets of Chinese medicines and their active compounds. Int J Mol Sci. 2016;17:893. doi: 10.3390/ijms17060893. - DOI - PMC - PubMed